LGM 2605
Alternative Names: LGM-2605Latest Information Update: 28 Mar 2025
At a glance
- Originator The Scripps Research Institute; University of Pennsylvania
- Developer LignaMed; National Institute of Allergy and Infectious Diseases
- Class Antiasthmatics; Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Asthma
- No development reported Chemotherapy-induced damage; Lung disorders; Pulmonary fibrosis; Radiation injuries
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Lung disorders in USA (PO)
- 28 Mar 2025 No recent reports of development identified for preclinical development in Pulmonary-fibrosis in USA (PO)
- 28 Mar 2025 No recent reports of development identified for preclinical development in Radiation-injuries in USA (Intranasal)